Patent · US Active

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

US10975081B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

Xiao Ding · Chesterfield, US
Yun Jin · Kowloon, CN
Qian Liu · Suzhou, CN
Feng Ren · Shanghai, CN
Yingxia Sang · Shanghai, CN
Luigi Piero Stasi · Verona, IT
Zehong Wan · King of Prussia, US
Hailong Wang · Nanhu, CN
Weiqiang XING · Shanghai, CN
Yang Zhan · Shanghai, CN
Baowei Zhao · Shanghai, CN

Key dates

Filing date	Jul 22, 2016
Grant date	Apr 13, 2021
Priority date	—
Expiry date	Oct 29, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.